Literature DB >> 15994286

Directing thrombin.

David A Lane1, Helen Philippou, James A Huntington.   

Abstract

Following initiation of coagulation as part of the hemostatic response to injury, thrombin is generated from its inactive precursor prothrombin by factor Xa as part of the prothrombinase complex. Thrombin then has multiple roles. The way in which thrombin interacts with its many substrates has been carefully scrutinized in the past decades, but until recently there has been little consideration of how its many functions are coordinated or directed. Any understanding of how it is directed requires knowledge of its structure, how it interacts with its substrates, and the role of any cofactors for its interaction with substrates. Recently, many of the interactions of thrombin have been clarified by crystal structure and site-directed mutagenesis analyses. These analyses have revealed common residues used for recognition of some substrates and overlapping surface exosites used for recognition by cofactors. As many of its downstream reactions are cofactor driven, competition between cofactors for exosites must be a dominant mechanism that determines the fate of thrombin. This review draws together much recent work that has helped clarify structure function relationships of thrombin. It then attempts to provide a cogent proposal to explain how thrombin activity is directed during the hemostatic response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994286     DOI: 10.1182/blood-2005-04-1710

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  90 in total

1.  Identification of exosite residues of factor Xa involved in recognition of PAR-2 on endothelial cells.

Authors:  Chandrashekhara Manithody; Likui Yang; Alireza R Rezaie
Journal:  Biochemistry       Date:  2012-03-15       Impact factor: 3.162

2.  Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study.

Authors:  Håkan Walfridsson; Birgitta Johansson; Anders Englund; Göran Kennebäck; Jonas Schwieler; Ole Kongstad; Karin Wåhlander; Anders R Malm; Nils Edvardsson
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

4.  Top of Basilar Artery Syndrome.

Authors:  Pokhraj P Suthar; Prakash J Rana; Chetan Mehta; Narottam A Patel
Journal:  J Clin Diagn Res       Date:  2015-07-01

Review 5.  New insights into modulation of thrombin formation.

Authors:  Henri M H Spronk; Julian I Borissoff; Hugo ten Cate
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

6.  An αIIbβ3- and phosphatidylserine (PS)-binding recombinant fusion protein promotes PS-dependent anticoagulation and integrin-dependent antithrombosis.

Authors:  Jian Jing; Yanna Sun
Journal:  J Biol Chem       Date:  2019-02-25       Impact factor: 5.157

7.  Shear tango: dance of the ADAMTS13/VWF complex.

Authors:  Rens de Groot; David A Lane
Journal:  Blood       Date:  2008-09-01       Impact factor: 22.113

8.  Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Georgi Georgiev; Anja Klemmer; Chelsea Brain; Paul Y Kim; Nicola J Mutch
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

9.  Polyphosphate binds with high affinity to exosite II of thrombin.

Authors:  N J Mutch; T Myles; L L K Leung; J H Morrissey
Journal:  J Thromb Haemost       Date:  2009-12-11       Impact factor: 5.824

10.  Occupancy of human EPCR by protein C induces β-arrestin-2 biased PAR1 signaling by both APC and thrombin.

Authors:  Ram Vinod Roy; Abdolreza Ardeshirylajimi; Peyman Dinarvand; Likui Yang; Alireza R Rezaie
Journal:  Blood       Date:  2016-08-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.